NovaBridge Biosciences presented Phase 1 dose‑expansion data for its bispecific 4‑1BB × PD‑L1 antibody ragistomig at the European Society for Medical Oncology – Immuno‑Oncology Congress 2025 (ESMO‑IO 2025). The poster, delivered by Dr. Gerald Falchook of the Sarah Cannon Research Institute, showed that the 3 mg/kg every‑six‑weeks (Q6W) schedule produced a markedly improved safety profile while maintaining antitumor activity.
The Q6W cohort had only 5 % of patients with grade 3 or higher liver‑function‑test elevation, compared with 40 % on the 3 mg/kg every‑two‑weeks (Q2W) schedule. Disease‑control rates were 58.8 % for Q6W versus 64.3 % for Q2W, and objective‑response rates were 11.8 % versus 28.6 %. Immune‑engagement metrics were comparable between the two schedules, indicating that the extended interval does not compromise efficacy.
These findings support moving ragistomig into combination studies for relapsed or refractory solid tumors. The extended therapeutic window offered by the Q6W schedule is expected to facilitate broader clinical use and improve patient convenience. NovaBridge is eager to initiate combination trials in partnership with ABL Bio, a collaboration that aligns with the company’s strategy to accelerate development of transformative therapies.
Dr. Phillip Dennis, NovaBridge’s Chief Medical Officer, said the data reinforce ragistomig’s potential to overcome checkpoint‑inhibitor resistance and that the company is ready to launch combination studies. CEO Sean Fu added that the results build on earlier data and underscore the company’s commitment to partnering for accelerated development.
NovaBridge, which rebranded from I‑Mab on October 30 2025, presented the data at ESMO‑IO 2025, which ran from December 10‑12. This milestone is a key step toward future regulatory submissions and signals progress in the company’s pipeline.
While specific market‑reaction data are not available, the clinical results represent a significant advancement for NovaBridge’s flagship asset and are likely to influence investor perception of the company’s growth prospects.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.